Heal D J, Butler S A, Hurst E M, Buckett W R
Research Department, Boots Company PLC, Nottingham, England.
J Neurochem. 1989 Oct;53(4):1019-25. doi: 10.1111/j.1471-4159.1989.tb07389.x.
The beta 1- and beta 2-adrenoceptor populations in rat cortex were individually quantified by labelling all of the receptors with [3H]dihydroalprenolol and displacing with isoprenaline (200 microM) or CGP 20712A (1-(2-[(3-carbamoyl-4-hydroxy)phenoxy]ethylamino)-3-[4-(1-methyl-4- trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol methanesulphonate; 100 nM) to define total beta-adrenoceptors and beta 1-adrenoceptors, respectively. Binding parameters for beta 2-adrenoceptors were calculated by the difference. Oral administration of the monoamine reuptake inhibitors sibutramine HCl (3 mg/kg), amitriptyline (10 mg/kg), desipramine (10 mg/kg), or zimeldine (10 mg/kg) for 10 days decreased the total number of beta-adrenoceptors present in rat cortex. This effect was entirely due to a reduction in the number of beta 1-adrenoceptors. Similarly, 10 days of treatment with the monoamine oxidase inhibitor tranylcypromine (10 mg/kg p.o.) or five electroconvulsive shocks (ECSs; 200 V, 2 s) spread over this period also down-regulated beta-adrenoceptors by reducing the content of the beta 1-subtype. By contrast, treatment with clenbuterol (5 mg/kg p.o.) for 10 days reduced the number of cortical beta-adrenoceptors by an effect on the beta 2-adrenoceptor population. The effects of short-term treatment with these drugs were also investigated, and, using the doses shown above, the results of 3 days of administration or a single ECS were determined. Sibutramine HCl and desipramine were alone in producing a reduction in number of beta-adrenoceptors after 3 days. Once again, this was exclusively due to a loss of beta 1-adrenoceptors.(ABSTRACT TRUNCATED AT 250 WORDS)
通过用[³H]二氢烯丙洛尔标记所有受体,并用异丙肾上腺素(200μM)或CGP 20712A(1-(2-[(3-氨基甲酰基-4-羟基)苯氧基]乙氨基)-3-[4-(1-甲基-4-三氟甲基-2-咪唑基)苯氧基]-2-丙醇甲磺酸盐;100 nM)置换,分别对大鼠皮质中的β1-和β2-肾上腺素能受体群体进行单独定量,以确定总β-肾上腺素能受体和β1-肾上腺素能受体。β2-肾上腺素能受体的结合参数通过差值计算得出。口服单胺再摄取抑制剂盐酸西布曲明(3 mg/kg)、阿米替林(10 mg/kg)、地昔帕明(10 mg/kg)或齐美利定(10 mg/kg)10天,可降低大鼠皮质中β-肾上腺素能受体的总数。这种效应完全是由于β1-肾上腺素能受体数量的减少。同样,在此期间口服单胺氧化酶抑制剂反苯环丙胺(10 mg/kg)10天或进行五次电惊厥休克(ECS;200 V,2 s),也通过减少β1-亚型的含量下调了β-肾上腺素能受体。相比之下,口服克仑特罗(5 mg/kg)10天通过对β2-肾上腺素能受体群体的作用减少了皮质β-肾上腺素能受体的数量。还研究了这些药物短期治疗的效果,并使用上述剂量确定了给药3天或单次ECS的结果。仅盐酸西布曲明和地昔帕明在给药3天后可使β-肾上腺素能受体数量减少。同样,这完全是由于β1-肾上腺素能受体的丧失。(摘要截短至250字)